Improvement of relapse or infection incidence in patients with refractory leukemia receiving allogeneic hematopoietic stem cell transplantation

Research Project

Project/Area Number	24701031
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Multi-year Fund
Research Field	Clinical oncology
Research Institution	Osaka City University
Principal Investigator	KOH HIDEO 大阪市立大学, 大学院医学研究科, 講師 (90419698)
Research Collaborator	NAKAMAE Hirohisa 大阪市立大学, 大学院医学研究科, 准教授 (30364003)
Project Period (FY)	2012-04-01 – 2016-03-31
Project Status	Completed (Fiscal Year 2015)
Budget Amount *help	¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000) Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000) Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000) Fiscal Year 2013: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000) Fiscal Year 2012: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Keywords	分子疫学 / 同種造血幹細胞移植 / 腫瘍再発抑制 / 感染免疫 / ゲノム疫学
Outline of Final Research Achievements	We examined the impact of killer immunoglobulin-like receptor (KIR) genotype/haplotype and single nucleotide polymorphisms (SNPs) of NKG2D, Toll-like receptor (TLR) 4, TLR9, CTLA-4 and HMGB-1 on relapse-free survival (RFS) of 121 patients with refractory hematological disorders who received related-donor hematopoietic cell transplantation (HCT). In analysis of the patients receiving HLA haploidentical peripheral blood stem cell transplantation using posttransplantation cyclophosphamide, KIR haplotype AA recipients from KIR Bx donors showed marginally significantly higher RFS than those from KIR AA donors (48% vs 9%, Log-rank P=0.088). There seemed to be no significant associations between RFS and KIR haplotype or the above-mentioned SNPs in the patients receiving HLA matched/mismatched related-donor HCT.